

## CONFERENCE ABSTRACT

# Letrozole and anastrozole in early breast cancer postmenopausal patients in oncology department at Suez Canal University Hospital

Manar Montasser\*<sup>1</sup>, Ihab M.A. Hassanin<sup>2</sup>, Soheir E. Abdelmohsen<sup>2</sup>, Maha L. Zamzam<sup>2</sup>

<sup>1</sup>*Clinical Oncology, Suez Canal Authority Hospital, Suez Canal, Egypt*

<sup>2</sup>*Clinical Oncology and Nuclear Medicine Department, Suez Canal University, Suez Canal, Egypt*

**Received:** January 9, 2019

**Accepted:** January 10, 2019

**Online Published:** January 16, 2019

**DOI:** 10.5430/jst.v9n1p12

**URL:** <https://doi.org/10.5430/jst.v9n1p12>

### ABSTRACT

**Background:** There are limited data in the literature comparing the efficacy of aromatase inhibitors in postmenopausal hormonal receptor positive early breast cancer patients.

**Aim of study:** To compare the efficacy of letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.

**Methods:** A retrospective study with a mean follow-up period of 64 months (about 5 years) for 74 files of early invasive postmenopausal breast cancer hormonal receptor positive patients; 39 received letrozole and 35 received anastrozole, considering TTP as primary end point, and OS as second end points.

**Results:** Letrozole is not superior to anastrozole during the first 55 months of treatment (80% PFS at 5th year), and 80% OS benefit at 6th year. Overweight patients had better (90% PFS at 5th year) than obese patients (60% PFS at 5th year).

**Conclusion:** Letrozole is not superior to anastrozole in efficacy in early invasive hormonal receptor positive breast cancer postmenopausal patients during the first 5 years of treatment; however, Letrozole 2nd line after tamoxifen is superior to anastrozole 2nd line after tamoxifen in treating obese patients with early invasive hormone receptor positive breast cancer.

**Key Words:** Survival, TTP, PFS, AI

---

\***Correspondence:** Manar Montasser; Email: manarmontasser17@gmail.com; Address: Clinical oncology specialist, Suez Canal Authority Hospital, Egypt.